IV Ketorolac on Platelet Function Post-Cesarean Delivery

Launched by BETH ISRAEL DEACONESS MEDICAL CENTER · Jan 13, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called ketorolac on platelet function in women who have just had a cesarean delivery, which is a common type of surgery to deliver a baby. While ketorolac can help manage pain after the surgery and reduce the need for stronger pain medications, researchers want to understand how it affects blood platelets, which are important for clotting and preventing excessive bleeding. They will use specific tests to measure how well the platelets work after the medication is given.

To be eligible for this study, participants must be pregnant and scheduled for a routine cesarean section, with a single baby and at least 37 weeks into their pregnancy. However, women with certain health issues, such as severe pre-eclampsia or a history of bleeding disorders, cannot participate. If you join this trial, you can expect to receive ketorolac during your cesarean delivery, and the researchers will monitor your platelet function afterward to gather important information about the medication's effects. This study is currently active and aims to improve pain management practices for new mothers while ensuring their safety.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant
• • Undergoing routine, scheduled cesarean section
• • Gestation \>37 weeks
• • Singleton gestation
• • Intraoperative anesthesia - 1.5 ml of intrathecal bupivicaine 0.75%, 25mcg of intrathecal fentanyl and 250 mcg of intrathecal morphine via Spinal or Combined Spinal Epidural
• Exclusion Criteria:
• • Pre-eclampsia with severe features or HELLP
• • Allergy to NSAIDs
• • Pre-existing bleeding disorder
• • Other major risk factor for postpartum hemorrhage (placenta accreta, large uterine fibroid)
• • Chronic kidney disease
• • Plt count less than 100k
• • Gastric ulcer or gastric bleeding
• • Pre-existing uterine bleeding or disseminated intravascular coagulation
• • Patient or Obstetrician refusal
• • Intraoperative exclusion criteria - Postpartum hemorrhage (EBL \>1000 ml) or unplanned intraoperative extension of surgery